Active, not recruitingEarly Phase 1NCT05485207

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

Studying Interstitial cystitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stanford University
Principal Investigator
Amy D. Dobberfuhl, M.D.
Stanford University
Intervention
Transvaginal botulinum toxin A (BTA) injection(drug)
Enrollment
5 target
Eligibility
18 years · FEMALE
Timeline
20222025

Study locations (1)

Collaborators

McCormick and Gabilan Faculty Fellowship Award

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05485207 on ClinicalTrials.gov

Other trials for Interstitial cystitis

Additional recruiting or active studies for the same condition.

See all trials for Interstitial cystitis

← Back to all trials